Medicinal composition for treating chronic mastitis

Abstract

The invention relates to a medicinal composition for treating chronic mastitis. The medicinal composition is prepared from the following bulk medicaments in parts by weight: 150 parts of viburnum cylindricum leaf, 150 parts of officinal asparagus root, 90 parts of bottlebrush orchid, 80 parts of grosvener siraitia, 100 parts of purslane speedwell herb, 90 parts of asystasiella neesiana, 100 parts of scurrula limprichtii, 100 parts of hydnocarpus, 90 parts of west china hypericum, 80 parts of honeysuckle flower, 150 parts of mountain peanut, 60 parts of American ginseng, 100 parts of purple lythrum herb, 150 parts of horseweed herb, 90 parts of crab grass, 60 parts of polygonum criopolitanum, 60 parts of pedicularis resupinata, 100 parts of radix rehmanniae proparate, 100 parts of indigofera tinctoria, 60 parts of dendrobium lindleyi, 90 parts of ford manglietia fruit, 90 parts of smilax, 50 parts of evening primrose, 80 parts of ephedra herb, 60 parts of saxifraga unguiculata, 50 parts of cassia bark, 90 parts of white mustard seeds, 100 parts of common adenostema herb, 150 parts of tarenna, 90 parts of ligustrum quihoui and 90 parts of reboulia hemisphaerica. The medicinal composition for treating chronic mastitis, disclosed by the invention, is reasonable in prescription, has the characteristics of definite curative effect, safety, convenience and low cost, and does not have toxic or side effects.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating chronic mastitis. Background technique [0002] Chronic mastitis refers to a chronic protracted inflammation of the breast formed by residual inflammatory nodules or masses in the mammary gland or milk duct after acute mastitis. Clinically, it is characterized by breast agglomeration, firmness, constant skin color, and recurrent episodes, commonly known as "stiffness". The disease is generally not easy to purulent, ulcerated, and difficult to dissipate. However, when the patient's resistance is reduced, the original lesion may relapse acutely, resulting in pus, making the condition lingering and persistent. Contents of the invention [0003] The object of the present invention is to provide a pharmaceutical composition for treating chronic mastitis. [0004] In order to achieve the object of the present invention, the present invention provide...

AI Technical Summary

Problems solved by technology

The disease is generally not easy to purulent, ulcerated, and difficult to dissipate. However, when the patient's resistance is reduced, the original lesion may relapse acutely, resulting in pus, which makes the disease lingering and unhealed for a long time.

Images